Skip to main content

IVA · Inventiva S.A. · Documents

Track IVA — free
$3.14 -0.31 (-8.99%) At close · Nov 20 Play latest call Q2 2026 earnings call transcript
Market Cap
$750.78M
Shares
239.10M
Volume · Nov 20 3.02M Avg daily vol (3M) 2.37M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue 4.48M EUR down 51.3% 20-F filed Apr 8, 2026 Earnings call Q2 2026 earnings call Held Sep 28, 2026
2026
Oct 6
Current report 6-K
Current report

Inventiva will present three abstracts at AASLD The Liver Meeting® 2026, held November 5-9, 2026, in Denver, Colorado, concerning lanifibranor in MASH. Phase 3 NATiV3 topline results are expected in the fourth quarter of this year.

Sep 28
Current report 6-K
Current report

Inventiva S.A. completed a June 2026 refinancing, drew €75.0 million, had €166.1 million in cash and cash equivalents at June 30, 2026, and completed NATiV3’s final patient visit, targeting topline results in the fourth quarter of 2026.

Read from the first part of this long document
Apr 8
Annual report 20-F FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue 4.48M EUR ▼ 51.3% Diluted EPS -1.90 EUR
2025
Apr 15
Annual report 20-F FY2024, ended Dec 31
Annual report for FY2024
Revenue 9.2M EUR ▼ 47.4% Net loss 184.21M EUR Diluted EPS -3.08 EUR
Showing 1–50 of 169 documents
Key facts CIK 1756594 CUSIP 46124U107 13F (30d) 94 filings 93 filers Visit website Investor relations